hb0056
mAbexperimentalBi-specific
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2024 (NCT06612970)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Interleukin-11INHIBITOR
IL11 inhibitor
- Thymic stromal lymphopoietinINHIBITOR
TSLP inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06612970 | Phase 1 | Nov 1, 2024 | New Zealand Clinical Research, Zhejiang Huahai Pharmaceutical Co., Ltd. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| New Zealand Clinical Research | For profit | 1 | 0 | 1 | 2024 |
| Zhejiang Huahai Pharmaceutical Co., Ltd. | For profit | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1